These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15117326)

  • 1. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
    Sulkowski MS; Wasserman R; Brooks L; Ball L; Gish R
    J Viral Hepat; 2004 May; 11(3):243-50. PubMed ID: 15117326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
    Dieterich DT; Wasserman R; Bräu N; Hassanein TI; Bini EJ; Bowers PJ; Sulkowski MS
    Am J Gastroenterol; 2003 Nov; 98(11):2491-9. PubMed ID: 14638354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection--a study in patients with chronic hepatitis C.
    Cheng PN; Jen CM; Young KC; Chen CY; Lu SN; Wang CS; Chang TT
    Hepatogastroenterology; 2003; 50(50):449-52. PubMed ID: 12749244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
    Pockros PJ; Shiffman ML; Schiff ER; Sulkowski MS; Younossi Z; Dieterich DT; Wright TL; Mody SH; Tang KL; Goon BL; Bowers PJ; Leitz G; Afdhal NH;
    Hepatology; 2004 Dec; 40(6):1450-8. PubMed ID: 15565613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.
    Hu CC; Weng CH; Lin CL; Tien HC; Kuo YL; Chien CH; Yen CL; Lin CY; Chien RN
    Ren Fail; 2012; 34(4):429-34. PubMed ID: 22264026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
    Zheng YH; He Y; Yang X; Gong GZ; Zhou HY; Zhang CY; Zhou W; Huang L; Ding PP; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):741-4. PubMed ID: 16248945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C.
    Sharvadze L; Tsertsvadze T; Gochitashvili N; Kakabadze T; Dolmazashvili E
    Georgian Med News; 2006 Aug; (137):62-5. PubMed ID: 16980747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
    J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
    Huang JF; Chuang WL; Dai CY; Chen SC; Lin ZY; Lee LP; Lee PL; Wang LY; Hsieh MY; Chang WY; Yu ML
    J Viral Hepat; 2006 Jun; 13(6):396-401. PubMed ID: 16842442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.
    De Franceschi L; Fattovich G; Turrini F; Ayi K; Brugnara C; Manzato F; Noventa F; Stanzial AM; Solero P; Corrocher R
    Hepatology; 2000 Apr; 31(4):997-1004. PubMed ID: 10733558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
    McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
    Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
    Bräu N
    J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.
    Jain AB; Eghtesad B; Venkataramanan R; Fontes PA; Kashyap R; Dvorchik I; Shakil AO; Kingery L; Fung JJ
    Liver Transpl; 2002 Nov; 8(11):1007-13. PubMed ID: 12424713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
    Balan V; Schwartz D; Wu GY; Muir AJ; Ghalib R; Jackson J; Keeffe EB; Rossaro L; Burnett A; Goon BL; Bowers PJ; Leitz GJ;
    Am J Gastroenterol; 2005 Feb; 100(2):299-307. PubMed ID: 15667486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
    Takaki S; Tsubota A; Hosaka T; Akuta N; Someya T; Kobayashi M; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Jul; 39(7):668-73. PubMed ID: 15293138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
    Bräu N; Rodriguez-Torres M; Prokupek D; Bonacini M; Giffen CA; Smith JJ; Frost KR; Kostman JR
    Hepatology; 2004 Apr; 39(4):989-98. PubMed ID: 15057903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
    Fouad YM; Khalaf H; Ibraheem H; Rady H; Helmy AK
    Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
    Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
    J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.